Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.57 |
| ▸ | GSK3B | P49841 | 12/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31149832 | 1.00 | PTPN1 (0.57) | PTPN1GSK3BCES2CES1NPC1 | |
| SCHEMBL2953875 | 0.85 | PTPN1 (0.57) | PTPN1GSK3BCES2CES1MAOB | |
| SCHEMBL246840 | 0.85 | ACHE (0.42) | PTPN1GSK3BCES2CES1NPC1 | |
| SCHEMBL28037289 | 0.85 | CES2 (0.41) | PTPN1GSK3BCES2CES1NPC1 | |
| SCHEMBL29628387 | 0.84 | PTPN1 (0.61) | PTPN1GSK3BCES2CES1NPC1 | |
| SCHEMBL366866 | 0.84 | PTPN1 (0.61) | PTPN1GSK3BCES2CES1NPC1 | |
| SCHEMBL3013333 | 0.83 | MAPT (0.50) | NPC1RAB9A | |
| SCHEMBL3995406 | 0.82 | GSK3B (0.59) | PTPN1GSK3B | |
| SCHEMBL5378544 | 0.80 | KMT2A (0.49) | NPC1RAB9A | |
| SCHEMBL2555281 | 0.80 | MAOB (0.40) | PTPN1CES2CES1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115484825-B | Phenyl compound and method for controlling plant disease | 住友化学株式会社 | 2025-06-24 | — | — | CN | disclosed |
| CN-115484825-A | Phenyl compound and method for controlling plant disease | 住友化学株式会社 | 2022-12-16 | — | — | CN | disclosed |
| WO-2021215480-A1 | PHENYL COMPOUND AND PLANT DISEASE CONTROL METHOD | 住友化学株式会社 (JP) | 2021-10-28 | — | — | WO | disclosed |
| US-10442788-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10301255-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170022150-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
| WO-2017015451-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| WO-2016161268-A1 | HEPATITIS B ANTVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160289212-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2016-10-06 | — | — | US | disclosed |
| EP-2758380-B1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040180921-A1 | Substituted imidazo[1,2-a]pyridine derivatives | MUTEL VINCENT (FR) | 2004-09-16 | — | — | US | disclosed |
| US-20040072876-A1 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1381363-A1 | IMIDAZO [1,2-A]-PYRIDINE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-21 | — | — | EP | disclosed |
| US-20030212096-A1 | Substituted imidazo [1,2-a] pyridine derivatives | MUTEL VINCENT (FR) | 2003-11-13 | — | — | US | disclosed |
| EP-1348706-A1 | SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-10-01 | — | — | EP | disclosed |
| US-6596731-B2 | An imidazo(1,2-a)pyridine derivative useful for treating chronical or acute neurological disorders, cognitive disorders and memory deficits | HOFFMANN-LA ROCHE INC. | 2003-07-22 | — | — | US | disclosed |
| US-20020188128-A1 | Substituted imidazo[1,2-A] pyridine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2002-12-12 | — | — | US | disclosed |
| WO-2002092086-A1 | IMIDAZO (1,2-A)-PYRIDINE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301255-B2 | Hepatitis B antiviral agents | HAVCR2, ZC3HAV1, SLC10A1 | PTPN1 1304/4885GSK3B 149/4885CES2 1700/4885 |
| US-20160289212-A1 | HEPATITIS B ANTIVIRAL AGENTS | ZC3HAV1, HAVCR2, SLC10A1 | PTPN1 645/4885GSK3B 76/4885CES2 2119/4885 |
| US-20040072876-A1 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | CYP17A1, CYP21A2, HSD17B1 | PTPN1 769/4885GSK3B 1171/4885CES2 840/4885 |
| US-20170022150-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, ZC3HAV1, SLC10A1 | PTPN1 1304/4885GSK3B 149/4885CES2 1700/4885 |
| US-20030212096-A1 | Substituted imidazo [1,2-a] pyridine derivatives | GRM5, GRM1, GRIK5 | PTPN1 745/4885GSK3B 3738/4885CES2 1935/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | PTPN1 1920/4885GSK3B 2185/4885CES2 1479/4885 |
| US-20040180921-A1 | Substituted imidazo[1,2-a]pyridine derivatives | GRM5, GRM1, GRIK5 | PTPN1 745/4885GSK3B 3738/4885CES2 1935/4885 |
| US-10442788-B2 | Hepatitis B antiviral agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | PTPN1 659/4885GSK3B 79/4885CES2 2136/4885 |
| US-20020188128-A1 | Substituted imidazo[1,2-A] pyridine derivatives | GRM5, GRM1, GRIK5 | PTPN1 745/4885GSK3B 3738/4885CES2 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.